RGCC

What RGCC does

RGCC Group is a Swiss precision medicine company founded in 2004 by genetics pioneer Dr. Ioannis Papasotiriou and headquartered in Zug, Switzerland. The company operates through three integrated divisions: RGCC International provides personalized cancer diagnostics using liquid biopsy technology, circulating tumor cell (CTC) analysis, circulating tumor DNA (ctDNA) analysis, and biomarker profiling; Welmedis develops targeted therapeutics and conducts drug discovery using the RGCC target identification platform, identifying novel targets for small-molecule therapeutics; and Biocentaur offers direct-to-consumer molecular biology tests for disease risk assessment, diagnosis, and treatment response determination. In April 2024, RGCC launched Onco-D-clare, a cancer detection test that combines molecular biology with artificial neural networks to identify cancer before symptoms appear.

RGCC serves four primary customer segments: cancer patients and survivors seeking personalized treatment insights, healthcare providers and oncologists who order diagnostic tests and integrate results into treatment plans, pharmaceutical and biotechnology companies leveraging the company's CRO services and target identification platform, and health-conscious individuals accessing Biocentaur's consumer testing services. The company distributes through regional web platforms serving North America (myrgcc.com), Southeast Asia (rgccsea.com), and European markets (rgcc-international.com), combining direct-to-consumer self-serve ordering with direct enterprise sales for clinical research and pharmaceutical collaborations. The company employs 51-100 staff and operates under GDPR, Swiss FADP, and GMP practices.

Revenue mechanics span four streams: recurring diagnostic testing services (RGCC International), one-time consumer health tests (Biocentaur), licensing and royalty arrangements for drug discovery (Welmedis), and professional services for CRO engagements. Pricing is quote-based and not publicly disclosed. RGCC is founder-owned and bootstrapped, having consistently declined external funding since 2004 to preserve scientific independence. The company competes in a market (tumor marker testing) projected to reach $27.23 billion by 2030 at a 7.9% CAGR, driven by demand for early cancer detection, precision oncology adoption, and companion diagnostics.

Name

RGCC

Legal name

RGCC International GmbH

Website

https://rgcc-group.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

RGCC Group is a Swiss precision medicine company that delivers personalized cancer diagnostics through liquid biopsy and biomarker analysis via RGCC International, drug discovery services via Welmedis, and direct-to-consumer health testing via Biocentaur, serving cancer patients, healthcare providers, and pharmaceutical clients globally.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Clinical Research & Trial Central Laboratories (HLAFAMAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Liquid biopsy diagnostics
• Cancer genetic testing
• Precision oncology
• Circulating tumor cell analysis
• Drug discovery services

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Cancer Diagnostic Testing Services: RGCC International generates revenue through personalized blood tests (liquid biopsy) and cancer diagnostic services, providing tumor profiling and biomarker analysis for individual patients
2. Consumer Health Testing: Biocentaur division offers direct-to-consumer disease risk assessment, diagnostic, and treatment response tests for preventive healthcare decisions
3. Drug Discovery and Therapeutic Development: Welmedis division develops targeted therapeutics and provides drug discovery services using RGCC's target identification platform, identifying novel targets for small-molecule therapeutics
4. Clinical Research Services: CRO services accelerating clinical trial readiness and regulatory compliance across Europe, supporting pharmaceutical and biotechnology clients

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Core offering

RGCC provides advanced cancer diagnostics through proprietary liquid biopsy technology, including circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) analysis for clinicians and patients. The company operates three divisions: RGCC International (clinical cancer diagnostics for healthcare providers), Welmedis (drug discovery and pharmaceutical development services), and Biocentaur (consumer-directed health and genetic tests).

Product overview

RGCC Group operates as a fully integrated healthcare company with three main business divisions. RGCC International provides personalized cancer testing through liquid biopsies and biomarker analyses. Welmedis focuses on drug discovery and targeted therapeutics development. Biocentaur offers disease diagnostic and genetic predisposition tests. In April 2024, RGCC launched Onco-D-clare, an AI-powered cancer detection test that combines molecular biology with artificial neural networks to identify cancer before symptoms appear.

Differentiator

Problem solved

Functional benefit

Brands

• Onco-D-clare: Cancer detection test combining molecular biology with artificial neural networks to identify cancer before symptoms appear, launched April 2024

Products and services

• RGCC International Cancer Diagnostics

Quantifiable outcome

• Onco-D-clare can identify cancer before symptoms appear
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Guardant Health: Guardant Health is a leading liquid-biopsy company offering oncology liquid biopsy tests (Guardant360, Guardant Reveal for MRD) for tumor profiling and recurrence monitoring—directly overlapping RGCC's liquid-biopsy diagnostic franchise and oncology customer base.
• Natera: Natera offers Signatera, a tumor-informed ctDNA MRD test, alongside broader oncology and reproductive health diagnostics. It directly competes with RGCC in oncology liquid biopsy and shares the same customer base of oncologists and clinical researchers.
• Exact Sciences: Exact Sciences (Cologuard, Oncotype DX, Oncodetect MRD test) is a major cancer diagnostics competitor covering screening, tumor profiling, and MRD—the same continuum of use cases that RGCC International targets.
• Tempus AI: Tempus AI combines molecular profiling with AI/ML-driven insights for oncology and is increasingly competing in liquid biopsy. It mirrors RGCC's positioning of pairing molecular data with artificial intelligence for clinical decision support.
• Caris Life Sciences: Caris offers molecular profiling (MI Profile, MI Cancer Seek) plus AI-driven analytics. It directly overlaps RGCC's liquid-biopsy + biomarker + AI positioning in precision oncology.
• NeoGenomics: NeoGenomics operates a global oncology-focused clinical laboratory business offering tumor profiling and liquid biopsy services, directly comparable to RGCC International's clinical-diagnostics service line.

Broad incumbents

• Foundation Medicine: Foundation Medicine (a Roche subsidiary) offers comprehensive genomic profiling of solid tumors via FoundationOne CDx. It competes directly with RGCC's tumor-profiling services while operating at significantly larger scale and with deep pharma partnership distribution.
• BIO-Techne: BIO-Techne provides life-science research reagents, including exosome diagnostics (ExoDx) for prostate cancer, and serves as a broader life-science tools incumbent with adjacent oncology-diagnostic exposure to RGCC's biomarker work.

Emerging players

• Personalis: Personalis offers ultra-sensitive ctDNA-based MRD testing (NeXT Personal) and tumor profiling, overlapping RGCC's liquid biopsy diagnostics, particularly in the MRD subsegment.
• VolitionRx: VolitionRx is developing blood-based cancer diagnostic tests using nucleosome-based biomarkers. It is a smaller competitor in liquid-biopsy cancer detection with overlapping early-detection ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/RGCCGroup
• Facebookfacebook.com/RGCC.International

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RGCC